Back to Search
Start Over
A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways.
- Source :
- Nature Biotechnology; Nov2020, Vol. 38 Issue 11, p1253-1256, 4p
- Publication Year :
- 2020
-
Abstract
- Abbreviated regulatory approval pathways for biosimilars were created to accommodate intellectual property protection, foster competition and lower drug prices, but their success in achieving these goals has been mixed. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10870156
- Volume :
- 38
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Nature Biotechnology
- Publication Type :
- Academic Journal
- Accession number :
- 146808139
- Full Text :
- https://doi.org/10.1038/s41587-020-0717-7